News & Updates

People living with HIV-1 (PLWH) who discontinued traditional non-nucleoside reverse transcriptase inhibitor (NNRTI)- and boosted integrase strand transfer inhibitor (INSTI)-based regimens have maintained viral suppression following their switch to the next-generation NNRTI ainuovirine coformulated with lamivudine and tenofovir DF (ANV/3TC/TDF), as shown by the 144-week open-label results from the SPRINT* post-study presented at ESCMID Global 2026.

A payer-perspective study from the University of Hong Kong (HKU) indicates that single-dose baloxavir is a more cost-effective outpatient treatment option for seasonal influenza than oseltamivir, despite baloxavir’s higher acquisition cost.

An open-label extension (OLE) study demonstrates the long-term safety, tolerability, and efficacy of atogepant for migraine prevention.

Scalp cooling (or scalp hypothermia) reduces chemotherapy-induced alopecia, alleviates psychological distress, and improves quality of life (QoL) in patients with primary gynaecologic cancers receiving carboplatin plus paclitaxel, the single-centre, randomized controlled CHARM trial has shown. 

Treatment with colchicine and famotidine plus loratadine, in addition to specialist supportive care, can substantially ease severe fatigue among patients suffering from long COVID, as shown by the results of the STIMULATE ICP trial.